Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors.
Grigoriou M, Banos A, Hatzioannou A, Kloetgen A, Kouzis P, Aggouraki D, Zakopoulou R, Bamias G, Kassi E, Mavroudis D, Bamias A, Boumpas DT, Tsirigos A, Gogas H, Alissafi T, Verginis P.
Grigoriou M, et al. Among authors: banos a.
Cancer Immunol Res. 2021 Jul;9(7):726-734. doi: 10.1158/2326-6066.CIR-20-0969. Epub 2021 Apr 5.
Cancer Immunol Res. 2021.
PMID: 33820810
Free PMC article.